Publication

The Facts About Sexual (Dys)function in Schizophrenia: An Overview of Clinically Relevant Findings

de Boer, M. K., Castelein, S., Wiersma, D., Schoevers, R. A. & Knegtering, H., May-2015, In : Schizophrenia Bulletin. 41, 3, p. 674-686 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

de Boer, M. K., Castelein, S., Wiersma, D., Schoevers, R. A., & Knegtering, H. (2015). The Facts About Sexual (Dys)function in Schizophrenia: An Overview of Clinically Relevant Findings. Schizophrenia Bulletin, 41(3), 674-686. https://doi.org/10.1093/schbul/sbv001

Author

de Boer, Marrit K ; Castelein, Stynke ; Wiersma, Durk ; Schoevers, Robert A ; Knegtering, Henderikus. / The Facts About Sexual (Dys)function in Schizophrenia : An Overview of Clinically Relevant Findings. In: Schizophrenia Bulletin. 2015 ; Vol. 41, No. 3. pp. 674-686.

Harvard

de Boer, MK, Castelein, S, Wiersma, D, Schoevers, RA & Knegtering, H 2015, 'The Facts About Sexual (Dys)function in Schizophrenia: An Overview of Clinically Relevant Findings', Schizophrenia Bulletin, vol. 41, no. 3, pp. 674-686. https://doi.org/10.1093/schbul/sbv001

Standard

The Facts About Sexual (Dys)function in Schizophrenia : An Overview of Clinically Relevant Findings. / de Boer, Marrit K; Castelein, Stynke; Wiersma, Durk; Schoevers, Robert A; Knegtering, Henderikus.

In: Schizophrenia Bulletin, Vol. 41, No. 3, 05.2015, p. 674-686.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

de Boer MK, Castelein S, Wiersma D, Schoevers RA, Knegtering H. The Facts About Sexual (Dys)function in Schizophrenia: An Overview of Clinically Relevant Findings. Schizophrenia Bulletin. 2015 May;41(3):674-686. https://doi.org/10.1093/schbul/sbv001


BibTeX

@article{1351b2ad22ca484fa585ee840684e642,
title = "The Facts About Sexual (Dys)function in Schizophrenia: An Overview of Clinically Relevant Findings",
abstract = "A limited number of studies have evaluated sexual functioning in patients with schizophrenia. Most patients show an interest in sex that differs little from the general population. By contrast, psychiatric symptoms, institutionalization, and psychotropic medication contribute to frequently occurring impairments in sexual functioning. Women with schizophrenia have a better social outcome, longer lasting (sexual) relationships, and more offspring than men with schizophrenia. Still, in both sexes social and interpersonal impairments limit the development of stable sexual relationships. Although patients consider sexual problems to be highly relevant, patients and clinicians not easily discuss these spontaneously, leading to an underestimation of their prevalence and contributing to decreased adherence to treatment. Studies using structured interviews or questionnaires result in many more patients reporting sexual dysfunctions. Although sexual functioning can be impaired by different factors, the use of antipsychotic medication seems to be an important factor. A comparison of different antipsychotics showed high frequencies of sexual dysfunction for risperidone and classical antipsychotics, and lower frequencies for clozapine, olanzapine, quetiapine, and aripiprazole. Postsynaptic dopamine antagonism, prolactin elevation, and alpha(1)-receptor blockade may be the most relevant factors in the pathogenesis of antipsychotic-induced sexual dysfunction. Psychosocial strategies to treat antipsychotic-induced sexual dysfunction include psychoeducation and relationship counseling. Pharmacological strategies include lowering the dose or switching to a prolactin sparing antipsychotic. Also, the addition of a dopamine agonist, aripiprazole, or a phosphodiesterase-5 inhibitor has shown some promising results, but evidence is currently scarce.",
keywords = "antipsychotic, sexual dysfunction, schizophrenia, dopamine, prolactin, negative symptoms, RISPERIDONE-INDUCED HYPERPROLACTINEMIA, RANDOMIZED OPEN-LABEL, ANTIPSYCHOTIC-INDUCED HYPERPROLACTINEMIA, NEUROLEPTIC-INDUCED HYPERPROLACTINEMIA, PLACEBO-CONTROLLED TRIAL, QUALITY-OF-LIFE, DOUBLE-BLIND, PROLACTIN LEVELS, ERECTILE DYSFUNCTION, SCHIZOAFFECTIVE DISORDER",
author = "{de Boer}, {Marrit K} and Stynke Castelein and Durk Wiersma and Schoevers, {Robert A} and Henderikus Knegtering",
note = "{\circledC} The Author 2015. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2015",
month = "5",
doi = "10.1093/schbul/sbv001",
language = "English",
volume = "41",
pages = "674--686",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - The Facts About Sexual (Dys)function in Schizophrenia

T2 - An Overview of Clinically Relevant Findings

AU - de Boer, Marrit K

AU - Castelein, Stynke

AU - Wiersma, Durk

AU - Schoevers, Robert A

AU - Knegtering, Henderikus

N1 - © The Author 2015. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2015/5

Y1 - 2015/5

N2 - A limited number of studies have evaluated sexual functioning in patients with schizophrenia. Most patients show an interest in sex that differs little from the general population. By contrast, psychiatric symptoms, institutionalization, and psychotropic medication contribute to frequently occurring impairments in sexual functioning. Women with schizophrenia have a better social outcome, longer lasting (sexual) relationships, and more offspring than men with schizophrenia. Still, in both sexes social and interpersonal impairments limit the development of stable sexual relationships. Although patients consider sexual problems to be highly relevant, patients and clinicians not easily discuss these spontaneously, leading to an underestimation of their prevalence and contributing to decreased adherence to treatment. Studies using structured interviews or questionnaires result in many more patients reporting sexual dysfunctions. Although sexual functioning can be impaired by different factors, the use of antipsychotic medication seems to be an important factor. A comparison of different antipsychotics showed high frequencies of sexual dysfunction for risperidone and classical antipsychotics, and lower frequencies for clozapine, olanzapine, quetiapine, and aripiprazole. Postsynaptic dopamine antagonism, prolactin elevation, and alpha(1)-receptor blockade may be the most relevant factors in the pathogenesis of antipsychotic-induced sexual dysfunction. Psychosocial strategies to treat antipsychotic-induced sexual dysfunction include psychoeducation and relationship counseling. Pharmacological strategies include lowering the dose or switching to a prolactin sparing antipsychotic. Also, the addition of a dopamine agonist, aripiprazole, or a phosphodiesterase-5 inhibitor has shown some promising results, but evidence is currently scarce.

AB - A limited number of studies have evaluated sexual functioning in patients with schizophrenia. Most patients show an interest in sex that differs little from the general population. By contrast, psychiatric symptoms, institutionalization, and psychotropic medication contribute to frequently occurring impairments in sexual functioning. Women with schizophrenia have a better social outcome, longer lasting (sexual) relationships, and more offspring than men with schizophrenia. Still, in both sexes social and interpersonal impairments limit the development of stable sexual relationships. Although patients consider sexual problems to be highly relevant, patients and clinicians not easily discuss these spontaneously, leading to an underestimation of their prevalence and contributing to decreased adherence to treatment. Studies using structured interviews or questionnaires result in many more patients reporting sexual dysfunctions. Although sexual functioning can be impaired by different factors, the use of antipsychotic medication seems to be an important factor. A comparison of different antipsychotics showed high frequencies of sexual dysfunction for risperidone and classical antipsychotics, and lower frequencies for clozapine, olanzapine, quetiapine, and aripiprazole. Postsynaptic dopamine antagonism, prolactin elevation, and alpha(1)-receptor blockade may be the most relevant factors in the pathogenesis of antipsychotic-induced sexual dysfunction. Psychosocial strategies to treat antipsychotic-induced sexual dysfunction include psychoeducation and relationship counseling. Pharmacological strategies include lowering the dose or switching to a prolactin sparing antipsychotic. Also, the addition of a dopamine agonist, aripiprazole, or a phosphodiesterase-5 inhibitor has shown some promising results, but evidence is currently scarce.

KW - antipsychotic

KW - sexual dysfunction

KW - schizophrenia

KW - dopamine

KW - prolactin

KW - negative symptoms

KW - RISPERIDONE-INDUCED HYPERPROLACTINEMIA

KW - RANDOMIZED OPEN-LABEL

KW - ANTIPSYCHOTIC-INDUCED HYPERPROLACTINEMIA

KW - NEUROLEPTIC-INDUCED HYPERPROLACTINEMIA

KW - PLACEBO-CONTROLLED TRIAL

KW - QUALITY-OF-LIFE

KW - DOUBLE-BLIND

KW - PROLACTIN LEVELS

KW - ERECTILE DYSFUNCTION

KW - SCHIZOAFFECTIVE DISORDER

U2 - 10.1093/schbul/sbv001

DO - 10.1093/schbul/sbv001

M3 - Article

VL - 41

SP - 674

EP - 686

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 3

ER -

ID: 16328750